A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(16 sites)

Kenya

Victoria Biomedical Research Institute, Kisumu

Kenya Medical Research Institute, Nairobi

South Africa

JOSHA Research, Bloemfontein

South African Tuberculosis Vaccine Initiative, Cape Town

TASK Applied Science Pty Ltd. TASK Delft, Cape Town